Sadashiva S Karnik

List of Publications by Year
in descending order

99 papers	6,294 citations	61984 43 h-index	71685 76 g-index
103 all docs	103 docs citations	103 times ranked	6314 citing authors

#	Article	IF	Citations
1	Structural perspectives on the mechanism of signal activation, ligand selectivity and allosteric modulation in angiotensin receptors: IUPHAR Review 34. British Journal of Pharmacology, 2022, 179, 4461-4472.	5.4	5
2	Low-density lipoprotein encapsulated thiosemicarbazone metal complexes is active targeting vehicle for breast, lung, and prostate cancers. Drug Delivery, 2022, 29, 2206-2216.	5.7	6
3	Î²-Arrestinâ€"Biased Agonist Targeting the Brain AT ₁ R (Angiotensin II Type 1 Receptor) Increases Aversion to Saline and Lowers Blood Pressure in Deoxycorticosterone Acetateâ€"Salt Hypertension. Hypertension, 2021, 77, 420-431.	2.7	14
4	Receptors | Angiotensin Receptors. , 2021, , 110-121.		0
5	Current Trends in GPCR Allostery. Journal of Membrane Biology, 2021, 254, 293-300.	2.1	6
6	Novel allosteric ligands of the angiotensin receptor AT1R as autoantibody blockers. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	16
7	Integrated multiomics analysis identifies molecular landscape perturbations during hyperammonemia in skeletal muscle and myotubes. Journal of Biological Chemistry, 2021, 297, 101023.	3.4	10
8	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G proteinâ€coupled receptors. British Journal of Pharmacology, 2021, 178, S27-S156.	5.4	337
9	Angiotensin II receptors. , 2020, , 415-427.		12
10	SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. EBioMedicine, 2020, 58, 102907.	6.1	110
11	Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e007115.	2.2	6
12	Angiotensin Type 1 Receptor Blockers in Heart Failure. Current Drug Targets, 2020, 21, 125-131.	2.1	22
13	Mechanism of Hormone Peptide Activation of a GPCR: Angiotensin II Activated State of AT₁R Initiated by van der Waals Attraction. Journal of Chemical Information and Modeling, 2019, 59, 373-385.	5.4	23
14	Effect of novel GPCR ligands on blood pressure and vascular homeostasis. Methods in Cell Biology, 2019, 149, 215-238.	1.1	1
15	The nonâ€biphenylâ€tetrazole angiotensin AT₁ receptor antagonist eprosartan is a unique and robust inverse agonist of the active state of the AT₁ receptor. British Journal of Pharmacology, 2018, 175, 2454-2469.	5.4	7
16	Divergent Spatiotemporal Interaction of Angiotensin Receptor Blocking Drugs with Angiotensin Type 1 Receptor. Journal of Chemical Information and Modeling, 2018, 58, 182-193.	5.4	14
17	Small GTPases SAR1A and SAR1B regulate the trafficking of the cardiac sodium channel Nav1.5. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3672-3684.	3.8	20
18	Angiotensin II increases angiogenesis by NFâ€ÎºBâ€"mediated transcriptional activation of angiogenic factor AGGF1. FASEB Journal, 2018, 32, 5051-5062.	0.5	21

#	Article	IF	Citations
19	Retinal angiotensin II and angiotensin-(1-7) response to hyperglycemia and an intervention with captopril. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2018, 19, 147032031878932.	1.7	20
20	Significance of angiotensin 1â€“7 coupling with MAS1 receptor and other GPCRs to the reninâ€angiotensin system: IUPHAR Review 22. British Journal of Pharmacology, 2017, 174, 737-753.	5.4	71
21	Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism. Pharmacological Research, 2017, 123, 40-50.	7.1	68
22	Angiotensin Receptors: Structure, Function, Signaling and Clinical Applications. Journal of Cell Signaling, 2017, 01, .	0.3	48
23	A unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. PLoS ONE, 2017, 12, e0170456.	2.5	26
24	Connective tissue growth factor dependent collagen gene expression induced by MAS agonist AR234960 in human cardiac fibroblasts. PLoS ONE, 2017, 12, e0190217.	2.5	5
25	A unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks.. Journal of Biological Chemistry, 2016, 291, 14914.	3.4	1
26	Angiotensin Receptors: Structure, Function, Signaling and Clinical Applications. , 2016, 1, .		65
27	Structure of the Angiotensin Receptor Revealed by Serial Femtosecond Crystallography. Cell, 2015, 161, 833-844.	28.9	315
28	A Mechanism of Global Shape-dependent Recognition and Phosphorylation of Filamin by Protein Kinase A. Journal of Biological Chemistry, 2015, 290, 8527-8538.	3.4	14
29	G Protein-Coupled Receptors Directly Bind Filamin A with High Affinity and Promote Filamin Phosphorylation. Biochemistry, 2015, 54, 6673-6683.	2.5	23
30	Structure-Function Basis of Attenuated Inverse Agonism of Angiotensin II Type 1 Receptor Blockers for Active-State Angiotensin II Type 1 Receptor. Molecular Pharmacology, 2015, 88, 488-501.	2.3	28
31	International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli. Pharmacological Reviews, 2015, 67, 754-819.	16.0	245
32	Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor. Journal of Biological Chemistry, 2015, 290, 29127-29139.	3.4	145
33	MAS C-Terminal Tail Interacting Proteins Identified by Mass Spectrometry- Based Proteomic Approach. PLoS ONE, 2015, 10, e0140872.	2.5	8
34	Atypical Signaling and Functional Desensitization Response of MAS Receptor to Peptide Ligands. PLoS ONE, 2014, 9, e103520.	2.5	39
35	Critical Role for Lysine 685 in Gene Expression Mediated by Transcription Factor Unphosphorylated STAT3. Journal of Biological Chemistry, 2014, 289, 30763-30771.	3.4	48
36	Angiotensin II-regulated microRNA 483-3p directly targets multiple components of the reninâ€“angiotensin system. Journal of Molecular and Cellular Cardiology, 2014, 75, 25-39.	1.9	86

#	Article	IF	Citations
37	Constitutive Activity in the Angiotensin II Type 1 Receptor. Advances in Pharmacology, 2014, 70, 155-174.	2.0	31
38	Inducing Conformational Changes in G Protein-Coupled Receptors by Domain Coupling. Methods in Pharmacology and Toxicology, 2014, , 219-237.	0.2	1
39	Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertension Research, 2013, 36, 134-139.	2.7	47
40	Reassessment of the Unique Mode of Binding between Angiotensin II Type 1 Receptor and Their Blockers. PLoS ONE, 2013, 8, e79914.	2.5	14
41	Long Range Effect of Mutations on Specific Conformational Changes in the Extracellular Loop 2 of Angiotensin II Type 1 Receptor. Journal of Biological Chemistry, 2013, 288, 540-551.	3.4	30
42	Interaction of G-Protein Î²Î³ Complex with Chromatin Modulates GPCR-Dependent Gene Regulation. PLoS ONE, 2013, 8, e52689.	2.5	16
43	Angiotensin II Receptorâ€"Induced Cardiac Remodeling in Mice Without Angiotensin II. Hypertension, 2012, 59, 542-544.	2.7	7
44	Abilities of candesartan and other AT₁ receptor blockers to impair angiotensin II-induced AT₁ receptor activation after wash-out. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 76-83.	1.7	4
45	Domain coupling in GPCRs: the engine for induced conformational changes. Trends in Pharmacological Sciences, 2012, 33, 79-88.	8.7	70
46	There is no overkill in biochemistry. Resonance, 2012, 17, 1157-1164.	0.3	0
47	Small Molecules with Similar Structures Exhibit Agonist, Neutral Antagonist or Inverse Agonist Activity toward Angiotensin II Type 1 Receptor. PLoS ONE, 2012, 7, e37974.	2.5	23
48	Thymidine phosphorylase inhibits vascular smooth muscle cell proliferation via upregulation of STAT3. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 1316-1323.	4.1	12
49	Mechanism of GPCR-Directed Autoantibodies in Diseases. Advances in Experimental Medicine and Biology, 2012, 749, 187-199.	1.6	22
50	Review: Angiotensin II type 1 receptor blockers: class effects versus molecular effects. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2011, 12, 1-7.	1.7	129
51	MicroRNAsâ€"Regulators of Signaling Networks in Dilated Cardiomyopathy. Journal of Cardiovascular Translational Research, 2010, 3, 225-234.	2.4	16
52	Ligand-specific Conformation of Extracellular Loop-2 in the Angiotensin II Type 1 Receptor. Journal of Biological Chemistry, 2010, 285, 16341-16350.	3.4	63
53	Role of nuclear unphosphorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy. Cardiovascular Research, 2010, 85, 90-99.	3.8	70
54	Clinical and Pharmacotherapeutic Relevance of the Double-Chain Domain of the Angiotensin II Type 1 Receptor Blocker Olmesartan. Clinical and Experimental Hypertension, 2010, 32, 129-136.	1.3	22

#	Article	IF	Citations
55	Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors. Biochemical and Biophysical Research Communications, 2010, 391, 85-90.	2.1	46
56	A small difference in the molecular structure of angiotensin II receptor blockers induces AT1 receptor-dependent and -independent beneficial effects. Hypertension Research, 2010, 33, 1044-1052.	2.7	45
57	AT1 Receptor Induced Alterations in Histone H2A Reveal Novel Insights into GPCR Control of Chromatin Remodeling. PLoS ONE, 2010, 5, e12552.	2.5	4
58	Unique MicroRNA Profile in End-stage Heart Failure Indicates Alterations in Specific Cardiovascular Signaling Networks. Journal of Biological Chemistry, 2009, 284, 27487-27499.	3.4	121
59	A Protein Tyrosine Phosphatase Inhibitor, Pervanadate, Inhibits Angiotensin II-Induced Î²-Arrestin Cleavage. Molecules and Cells, 2009, 28, 25-30.	2.6	3
60	Functional Selectivity at Non-Opioid Peptide Receptors. , 2009, , 267-281.		0
61	Angiotensinergic stimulation of vascular endothelium in mice causes hypotension, bradycardia and attenuated angiotensin response. Journal of Molecular and Cellular Cardiology, 2008, 45, S24.	1.9	0
62	Site-specific Cleavage of G Protein-coupled Receptor-engaged Î²-Arrestin. Journal of Biological Chemistry, 2008, 283, 21612-21620.	3.4	3
63	Differential Bonding Interactions of Inverse Agonists of Angiotensin II Type 1 Receptor in Stabilizing the Inactive State. Molecular Endocrinology, 2008, 22, 139-146.	3.7	77
64	Angiotensin II and Its Receptor Subtypes in the Human Retina. , 2007, 48, 3301.		198
65	Manifold active-state conformations in GPCRs: Agonist-activated constitutively active mutant AT1receptor preferentially couples to Gq compared to the wild-type AT1receptor. FEBS Letters, 2007, 581, 2517-2522.	2.8	15
66	Model of the whole rat AT1 receptor and the ligand-binding site. Journal of Molecular Modeling, 2006, 12, 325-337.	1.8	29
67	Angiotensinergic stimulation of vascular endothelium in mice causes hypotension, bradycardia, and attenuated angiotensin response. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19087-19092.	7.1	37
68	Molecular Mechanism Underlying Inverse Agonist of Angiotensin II Type 1 Receptor. Journal of Biological Chemistry, 2006, 281, 19288-19295.	3.4	118
69	Constitutively Active Homo-oligomeric Angiotensin II Type 2 Receptor Induces Cell Signaling Independent of Receptor Conformation and Ligand Stimulation. Journal of Biological Chemistry, 2005, 280, 18237-18244.	3.4	80
70	Unconventional Homologous Internalization of the Angiotensin II Type-1 Receptor Induced by G-Proteinâ€"Independent Signals. Hypertension, 2005, 46, 419-425.	2.7	38
71	Multiple Signaling States of G-Protein-Coupled Receptors. Pharmacological Reviews, 2005, 57, 147-161.	16.0	229
72	Cardiac angiotensin II receptors as predictors of transplant coronary artery disease following heart transplantation. European Heart Journal, 2004, 25, 377-385.	2.2	18

#	Article	IF	Citations
73	â€œNetwork Leaningâ€•as a Mechanism of Insurmountable Antagonism of the Angiotensin II Type 1 Receptor by Non-peptide Antagonists. Journal of Biological Chemistry, 2004, 279, 15248-15257.	3.4	41
74	G-Protein-Dependent Cell Surface Dynamics of the Human Serotonin1AReceptor Tagged to Yellow Fluorescent Proteinâ€. Biochemistry, 2004, 43, 15852-15862.	2.5	74
75	Activation of Extracellular Signal-Activated Kinase by Angiotensin II-Induced Gq-Independent Epidermal Growth Factor Receptor Transactivation. Hypertension Research, 2004, 27, 765-770.	2.7	47
76	Activation of G-protein-coupled receptors: a common molecular mechanism. Trends in Endocrinology and Metabolism, 2003, 14, 431-437.	7.1	173
77	Independent Â-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10782-10787.	7.1	620
78	TM2-TM7 Interaction in Coupling Movement of Transmembrane Helices to Activation of the Angiotensin II Type-1 Receptor. Journal of Biological Chemistry, 2003, 278, 3720-3725.	3.4	50
79	Molecular Analysis of the Structure and Function of the Angiotensin II Type 1 Receptor. Hypertension Research, 2003, 26, 937-943.	2.7	95
80	Side-Chain Substitutions within Angiotensin II Reveal Different Requirements for Signaling, Internalization, and Phosphorylation of Type 1A Angiotensin Receptors. Molecular Pharmacology, 2002, 61, 768-777.	2.3	227
81	Constitutive Activation of Angiotensin II Type 1 Receptor Alters the Orientation of Transmembrane Helix-2. Journal of Biological Chemistry, 2002, 277, 24299-24305.	3.4	54
82	Analysis of structure-function from expression of G protein-coupled receptor fragments. Methods in Enzymology, 2002, 343, 248-259.	1.0	3
83	Ligand-independent signals from angiotensin II type 2 receptor induce apoptosis. EMBO Journal, 2000, 19, 4026-4035.	7.8	124
84	Agonist-induced Phosphorylation of the Angiotensin II (AT1A) Receptor Requires Generation of a Conformation That Is Distinct from the Inositol Phosphate-signaling State. Journal of Biological Chemistry, 2000, 275, 2893-2900.	3.4	95
85	Angiotensin II type 1 receptor-function affected by mutations in cytoplasmic loop CD. FEBS Letters, 2000, 470, 331-335.	2.8	15
86	Reversible inactivation of AT2angiotensin II receptor from cysteine-disulfide bond exchange. FEBS Letters, 2000, 484, 133-138.	2.8	23
87	Role of Aromaticity of Agonist Switches of Angiotensin II in the Activation of the AT1 Receptor. Journal of Biological Chemistry, 1999, 274, 7103-7110.	3.4	92
88	Role of Transmembrane Helix IV in G-protein Specificity of the Angiotensin II Type 1 Receptor. Journal of Biological Chemistry, 1999, 274, 35546-35552.	3.4	20
89	Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition. Journal of Hypertension, 1999, 17, 397-404.	0.5	66
90	Mechanism of Constitutive Activation of the AT1Receptor:Â Influence of the Size of the Agonist Switch Binding Residue Asn111â€. Biochemistry, 1998, 37, 15791-15798.	2.5	86

#	Article	IF	Citations
91	Distinct Multisite Synergistic Interactions Determine Substrate Specificities of Human Chymase and Rat Chymase-1 for Angiotensin II Formation and Degradation. Journal of Biological Chemistry, 1997, 272, 2963-2968.	3.4	72
92	Selective Reporter Expression in Mast Cells Using a Chymase Promoter. Journal of Biological Chemistry, 1997, 272, 2969-2976.	3.4	12
93	Transducin-Î± C-terminal Peptide Binding Site Consists of C-D and E-F Loops of Rhodopsin. Journal of Biological Chemistry, 1997, 272, 6519-6524.	3.4	81
94	The Active State of the AT1Angiotensin Receptor Is Generated by Angiotensin II Inductionâ€. Biochemistry, 1996, 35, 16435-16442.	2.5	149
95	Modulation of GDP Release from Transducin by the Conserved Glu134-Arg135 Sequence in Rhodopsin. Journal of Biological Chemistry, 1996, 271, 25406-25411.	3.4	98
96	The Docking of Arg2 of Angiotensin II with Asp281 of AT1 Receptor Is Essential for Full Agonism. Journal of Biological Chemistry, 1995, 270, 12846-12850.	3.4	144
97	Human Prochymase Activation. Journal of Biological Chemistry, 1995, 270, 2218-2223.	3.4	56
98	Tetrazole and Carboxylate Groups of Angiotensin Receptor Antagonists Bind to the Same Subsite by Different Mechanisms. Journal of Biological Chemistry, 1995, 270, 2284-2289.	3.4	142
99	Interaction of Phe8 of Angiotensin II with Lys199 and His256 of AT1 Receptor in Agonist Activation. Journal of Biological Chemistry, 1995, 270, 28511-28514.	3.4	100